Sachs European Biopharma Obesity Innovation Forum, June 11-12, 2025, Leipzig
Why Attend?
The current obesity pandemic is arguably the greatest challenge to 21st-century global health. The pharmaceutical market is estimated to exceed $100 billion by 2030, notwithstanding the pressure on payers. More positively, we are also learning more and more about the broad health benefits of GLP-1 medicines beyond even cardio-metabolic diseases.
The conference will provide insights into GLP-1 innovation, combinations, new foundational therapies, and precision medicine, while also addressing the challenge of manufacturing. Delegates will gain a comprehensive understanding of Europe’s market and its role in shaping global innovation.
What to Expect?
The 1st Annual EBOIF builds on the strong foundation of our San Francisco event, which attracted nearly 300 delegates. This European edition will highlight cutting-edge academic research, explore the European obesity landscape, and showcase the latest advances in drug development, treatment approaches, and investment opportunities. The event is supported by the City of Leipzig and hosted by leap:up GmbH.
